UnitedHealth Q2 Adjusted EPS Crushes Consensus at $6.38, Full-Year Guidance Raised and Buyback Target Doubled

summarizeSummary

UnitedHealth Group reported Q2 2026 adjusted EPS of $6.38, crushing the $4.90 consensus, and raised full-year adjusted EPS guidance to $19.50–$20.00. The company also doubled its share buyback target to at least $5 billion and lifted operating earnings and cash flow outlooks.

check_boxKey Events · Earnings and Guidance · UNH

• Q2 Adjusted EPS Blowout

  Adjusted EPS of $6.38 versus consensus of $4.90, driven by strong performance across UnitedHealthcare and Optum.

• Full-Year Guidance Raised Significantly

  2026 adjusted EPS outlook raised to $19.50–$20.00 from $17.75; operating earnings guidance increased to >$25.45B from >$24.0B.

• Share Buyback Target Doubled

  Full-year 2026 share repurchase target raised to at least $5.0B from ~$2.5B, with $4.0B already repurchased through mid-July.

• Medical Care Ratio Improves Sharply

  Medical care ratio fell to 86.7% from 89.4% YoY, reflecting benefit design changes, pricing discipline, and $860M in favorable prior period development.

auto_awesomeAnalysis · UNH · Finance

A massive Q2 beat sets the tone: adjusted EPS came in at $6.38, well above the $4.90 consensus, prompting a full-year 2026 adjusted EPS outlook raise to $19.50–$20.00 from $17.75. Operating earnings guidance jumped to over $25.45 billion, and the share repurchase target was doubled to at least $5 billion. The medical care ratio improved sharply to 86.7% from 89.4% a year ago, driven by pricing discipline and cost management. Cash flow from operations guidance was also hiked to roughly $24 billion. This is a clean, broad-based beat with significant upward revisions across all key metrics, reinforcing the turnaround narrative after a mixed Q1.